Results 11 to 20 of about 3,384,133 (256)
Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19
European Journal of Pharmacology, 2021 There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease (2019) (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a ...
B. Pitt +4 more
semanticscholar +1 more source
Frontiers in Oncology, 2023 BackgroundThe overall survival of peripheral T-cell lymphoma (PTCL) is dismal. Histone deacetylase (HDAC) inhibitors have exhibited promising treatment outcomes for PTCL patients. Therefore, this work aims to systematically evaluate the treatment outcome
Peipei Yang +12 more
doaj +1 more source
Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
Frontiers in Oncology, 2021 We have extended our analyses of HDAC inhibitor biology in sarcoma. The multi-kinase inhibitor axitinib interacted with multiple HDAC inhibitors to kill sarcoma cells.
Jane L. Roberts +3 more
doaj +1 more source
Cardiac HDAC3 Disruption Contributes to HDAC Inhibitor-Induced QT Prolongation. [PDF]
CellsHistone deacetylase (HDAC) inhibitors are approved for cancer treatment and are being investigated for a wide range of other diseases. Despite their therapeutic promise, clinical studies have reported cardiac side effects, particularly electrocardiogram (
Lu J +5 more
europepmc +2 more sources
Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC
Molecules, 2020 With five histone deacetylase (HDAC) inhibitors approved for cancer treatment, proteolysis-targeting chimeras (PROTACs) for degradation of HDAC are emerging as an alternative strategy for HDAC-targeted therapeutic intervention.
Jiangying Cao +7 more
doaj +1 more source
Azumamides A-E: Isolation, Synthesis, Biological Activity, and Structure–Activity Relationship
Molecules, 2022 Cyclic peptides are one of the important chemical groups in the HDAC inhibitor family. Following the success of romidepsin in the clinic, naturally occurring cyclic peptides with a hydrophilic moiety have been intensively studied to test their function ...
Sooheum Jo +4 more
doaj +1 more source
Cell Death and Disease, 2022 Histone deacetylase (HDAC) inhibitors and proteasome inhibitors have been approved by the FDA for the treatment of multiple myeloma and lymphoma, respectively, but have not achieved similar activity as single agents in solid tumors.
Jianling Bi +7 more
doaj +1 more source
A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. [PDF]
PLoS ONE, 2010 BACKGROUND: Lung cancer is the leading cause of cancer mortality worldwide, yet the therapeutic strategy for advanced non-small cell lung cancer (NSCLC) is limitedly effective.
Yen-An Tang +8 more
doaj +1 more source
Journal of Experimental & Clinical Cancer Research, 2021 Background Multiple myeloma (MM) is an incurable disease. The acquisition of resistance to drugs, including immunomodulatory drugs (IMiDs), has a negative effect on its prognosis.
Mitsuhito Hirano +19 more
doaj +1 more source
Redox Biology, 2021 Epithelial-to-mesenchymal transition (EMT) is an essential mechanism for development and wound healing, but in cancer it also mediates the progression and spread of aggressive tumors while increasing therapeutic resistance.
Thais Oliveira +5 more
doaj +1 more source